Aura Biosciences, Inc. Share Repurchases (Cash Paid)
Aura Biosciences, Inc. (AURA) reported Share Repurchases (Cash Paid) of $39.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfCommonStock · last filed 2026-08-11
- 2026-06-30: Payments for Repurchase of Common Stock 6 month $39.09M.
- 2025-06-30: Payments for Repurchase of Common Stock 6 month $0.00.
| Period end | Payments for Repurchase of Common Stock 6 month |
|---|---|
| 2026-06-30 | $39.09M 10-Q · filed 2026-08-11 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |